Introduction The global demand for GLP1 drugs like semaglutide is rapidly increasing due to rising diabetes and obesity cases
But there is a trade-off: DAC also increases the potential for side effects (more on that below)
Retatrutide is an investigational triple receptor agonist that simultaneously targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
He has also served on the speakers bureau of AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., Menarini/Berlin Chemie, Merck, Sharp & Dohme, Novo Nordisk, and Sun Pharma
Call your health care provider right away if you have any mental changes that are new, worse, or worry you food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)
2023;29(Suppl):S1731